PHILIP CINNAMON COMP
Medical Practice in Oklahoma City, OK

6423313, Jul 23, 2002

May 6, 1994

08/238987

Charles T. Esmon - Oklahoma City OK
Philip C. Comp - Oklahoma City OK

Oklahoma Medical Research Foundation - Oklahoma City OK

A61K 39395

4241381, 4241981, 435 723, 53038825, 53038826

Compositions, and methods of use thereof, for the inhibition of tumor growth and killing of solid tumors wherein the active agent is a compound blocking the Protein C system, preferably anti-Protein C antibody, anti-Protein S antibody, and C4b binding protein. In the most preferred embodiment, the Protein C blocking compound is provided in combination with a cytokine such as tumor necrosis factor (TNF), gamma interferon, interleukin-1, interleukin-2,p or granulocyte-macrophage colony stimulating factor, or a compound eliciting cytokine production such as endotoxin. Examples are provided demonstrating the administration of the Protein C blocking compound, alone or in combination with TNF or endotoxin, to animals having canine veneral tumors, a fibrosarcoma, and an adenocarcinoma, followed by significant tumor reduction.

5504064, Apr 2, 1996

Feb 19, 1993

8/021615

James H. Morrissey - Oklahoma City OK
Philip C. Comp - Oklahoma City OK

Oklahoma Medical Research Foundation - Oklahoma City OK

A61K 3514, A61K 3848, A61K 3816, C07K 14745

514 8

It has been discovered that it is possible to administer truncated tissue factor (not having the transmembrane region) (tTF) in combination with factor VIIa (FVIIa) or an activator of endogenous factor VII to treat bleeding disorders such as those resulting from hemophilia or cirrhosis of the liver. The tTF is administered to produce up to 10. mu. g tTF/ml of plasma. The FVIIa or FVII activator is administered to produce levels of between 40 ng FVIIa/ml and 700 ng FVIIa/ml of plasma. The effective dosages of both tTF and FVIIa/factor VII activator are significantly and surprisingly less than the administration of either alone to stop bleeding. Examples demonstrate safety and efficacy in normal and hemophilic dogs.

5147638, Sep 15, 1992

Aug 4, 1989

7/389617

Charles T. Esmon - Oklahoma City OK
Philip C. Comp - Oklahoma City OK

Oklahoma Medical Research Foundation - Oklahoma City OK

A61K 3700, A61K 3766, A61K 3900

424 858

Compositions, and methods of use thereof, for the inhibition of tumor growth and killing of tumors having extensive microcirculation wherein the active agent is a compound blocking the Protein C system, preferably anti-Protein C antibody, anti-Protein S antibody, and C4b binding protein. In the most preferred embodiment, the Protein C blocking compound is provided in combination with a cytokine such as tumor necrosis factor (TNF), gamma interferon, interleukin-1, interleukin-2 and granulocyte-macrophage colony stimulating factor. Examples are provided demonstrating the administration of the Protein C blocking compound, alone or in combination with TNF, to dogs having canine veneral tumors, or fibrosarcoma, and an adenocarcinoma, and pigs with melanoma followed by significant tumor reduction.

5374617, Dec 20, 1994

May 13, 1992

7/882202

James H. Morrissey - Oklahoma City OK
Philip C. Comp - Oklahoma City OK

Oklahoma Medical Research Foundation - Oklahoma City OK

A61K 3702

514 8

It has been discovered that it is possible to administer truncated tissue factor (not having the transmembrane region) (tTF) in combination with factor VIIa (F VIIa) to treat bleeding disorders such as those resulting from hemophilia or cirrhosis of the liver. The tTF is administered to produce up to 10. mu. g tTF/ml of plasma. The F VIIa is administered to produce levels of between 40 ng VIIa/ml and 4. mu. g F VIIa/ml of plasma. The effective dosages of both tTF and VIIa are significantly and surprisingly less than the administration of either alone to stop bleeding. Examples demonstrate safety and efficacy in normal and hemophilic dogs.

5504067, Apr 2, 1996

Oct 12, 1994

8/321777

James H. Morrissey - Oklahoma City OK
Philip C. Comp - Oklahoma City OK

Oklahoma Medical Research Foundation - Oklahoma City OK

A61K 3514, A61K 3848, A61K 3816, C07K 14745

514 8

It has been discovered that it is possible to administer truncated tissue factor, not having the transmembrane region (tTF) in combination with factor VIIa (FVIIa) to treat bleeding disorders such as those resulting from hemophilia or cirrhosis of the liver. Preferably, the tTF is administered to produce up to 10. mu. g tTF/ml of plasma. The FVIIa is administered to produce levels of between 40 ng FVIIa/ml and 4. mu. g FVIIa/ml of plasma. The effective dosages of both tTF and FVIIa are significantly and surprisingly less than the administration of either alone to stop bleeding. Examples demonstrate safety and efficacy in normal and hemophilic dogs.

7291333, Nov 6, 2007

Oct 14, 1994

08/323060

Philip C. Comp - Oklahoma City OK, US

Oklahoma Medical Research Foundation - Oklahoma City OK

A61K 39/395, C07K 16/44, C07K 16/18

4241451, 4241391, 4241521, 4241581, 4241721, 514 2, 514834, 53038825, 5303893, 435337

A method of inhibiting microvascular bleeding is provided. Antibody to protein C administered to a patient in a pharmaceutically acceptable carrier prevents anticoagulation by greater than 90% of activated protein C in human plasma.